Örebro Initiative Secures 2.5 Million SEK to Advance Rapid Diagnostics for Severe Infections

Örebro-based Clinical Genomics secures 2.5 million SEK to develop advanced metagenomic technology for rapid and accurate detection of severe infection pathogens and resistance.

    Key details

  • • 2.5 million kronor funding granted to Clinical Genomics Örebro for diagnostic development.
  • • The project develops a metagenomic method detecting microbial DNA directly from patient samples without cultivation.
  • • Technique identifies pathogens, antibiotic resistance, and genetic details rapidly and accurately.
  • • Aims to reduce unnecessary antibiotic use and improve diagnosis of challenging infections.
  • • Technology may help in outbreak management by detecting variants of known microorganisms.

Clinical Genomics Örebro, a joint venture between Region Örebro län and Örebro University, has launched a project supported by 2.5 million kronor to develop a pioneering metagenomic diagnostic technique aimed at faster, more precise detection of bacteria and viruses in severe infections. This cutting-edge approach captures microbial DNA directly from patient samples without the need for cultivation, enabling immediate identification of pathogens, antibiotic resistance, and detailed genetic profiles — crucial for infections often missed by traditional diagnostics.

Bianca Stenmark, Head of Unit at Clinical Genomics, explained that even minuscule amounts of pathogenic DNA can now be detected, a breakthrough for hard-to-diagnose conditions such as central nervous system or deep joint infections. Presently, many patients receive broad-spectrum antibiotics based on suspicion alone due to limitations in existing testing methods, which this technology aims to improve by offering accurate, rapid results.

Beyond enhancing individual patient care, this method could significantly reduce unnecessary antibiotic use and holds promise for outbreak control by identifying closely related variants of known microorganisms. The initiative is part of a larger collaboration under the Science for Life Laboratories, a government-funded institute focused on molecular biosciences and clinical health research, thereby leveraging high-level expertise for translational medical advancements.

This development represents a significant stride in Swedish healthcare, aiming to equip researchers and clinicians with advanced tools to better detect and combat severe infections through robust molecular diagnostics.

This article was translated and synthesized from Swedish sources, providing English-speaking readers with local perspectives.

Source comparison

The key details of this story are consistent across the source articles

The top news stories in Sweden

Delivered straight to your inbox each morning.